Henry Schein
HSIC
$84.96
-1.46%
Henry Schein Inc. is a global healthcare solutions company that distributes dental and medical supplies, equipment, and value-added services to office-based practitioners and alternative care sites, operating primarily through its Global Distribution and Value-Added Services segment (which generated roughly $2.95 billion of the most recent quarter's $3.47 billion in revenue), supplemented by smaller Global Specialty Products and Global Technology businesses. As one of the largest distributors to the fragmented dental and physician-practice market, Henry Schein occupies a scale-driven, relationship-intensive middleman position rather than a product-innovation or platform-disruptor role, with its competitive identity built on breadth of catalog, practice-integration technology, and financial services embedded into its distribution channel. The current investor narrative centers on a modest but persistent margin-recovery and earnings-growth story: after a multi-year stretch of depressed profitability, gross margin has climbed back toward 29.8% and operating margin to roughly 6.2%, while management leans heavily on share repurchases (over $500 million bought back across the trailing four quarters) to drive per-share results. Debate now hinges on whether low-single-digit revenue growth (up 3.95% year over year) and cost discipline can sustain the recent re-rating, or whether the stock's premium to its own historical valuation band and a soft third-quarter cash-flow print leave it vulnerable to disappointment.…
HSIC
Henry Schein
$84.96
Investment Opinion: Should I buy HSIC Today?
Rating: Hold, with a constructive tilt. The thesis is that HSIC is a low-growth, cash-generative dental and medical distributor whose earnings are being lifted by a genuine gross-margin recovery (29.79% in Q3 vs. 28.69% a year ago) and a roughly 7% share-count reduction from over $500 million of trailing buybacks, but whose 23.1x trailing PE already discounts much of that improvement, leaving only ~12.0% upside to the $96.60 average target against a 15-analyst consensus of 8 Buy / 7 Hold / 1 Sell. The risk/reward is positive but not compelling enough to chase at $86.22, roughly 6.5% below the $92.18 52-week high.
Supporting evidence is mixed but leans favorable on forward valuation. The stock trades at 14.35x the $7.25 consensus forward EPS versus 23.1x trailing — a 38% compression that implies a real earnings step-up — while the 0.70x price-to-sales and 12.65x EV/EBITDA are reasonable for a 29% gross-margin distributor. Revenue grew 3.95% year over year to $3.471 billion with no acceleration, but net income rose to $119 million (3.43% margin) from $101 million (3.02%), and trailing free cash flow of $529 million equates to a 5.7% FCF yield on the ~$9.2 billion market cap. The 3.23x PEG ratio and 2.83x P/B are the caution flags — the market is paying up relative to growth, and the 5.1x interest coverage ($42 million interest vs. $215 million operating income) shows leverage absorbs roughly a quarter of operating profit.
The biggest risks that could invalidate the thesis are a forward EPS miss (which would compress the multiple from both the 23.1x trailing and 14.35x forward sides simultaneously), a stall in gross-margin recovery back toward the 28.7% year-ago level, and lumpy cash conversion (Q1 free cash flow of -$136 million on a $278 million working-capital outflow). This Hold would upgrade to Buy on a pullback toward the low-$80s (implying ~12x forward EPS) or on evidence of gross margin holding above 30% for two consecutive quarters; it would downgrade to Sell if forward EPS estimates are cut below $7.00 or if the stock breaks the $82.50 November swing low. On balance the stock is fairly valued to slightly cheap on forward earnings but not statistically cheap on growth-adjusted or asset bases — a hold, not a bargain.
Sign up to view all
HSIC 12-Month Price Forecast
HSIC presents a balanced setup: the forward multiple of 14.35x is undemanding for a 5.7% FCF-yield distributor, and the margin and buyback trends are concrete, hard numbers rather than narrative. Against that, the 23.1x trailing PE sits near the top of its 19.3x-25.8x two-year band, revenue growth of 3.95% shows no acceleration, and the 72% spread in analyst targets signals genuine disagreement about whether the $7.25 forward EPS is achievable. The stock's 0.856 beta and 17.56% one-year return (5.29 points ahead of the S&P 500) support a defensive, relative-outperformance role, but the 3.95% three-month decline and consolidation below the $92.18 high suggest the easy money has been made. I would upgrade to bullish on a confirmed breakout above $92.18 or evidence of gross margin above 30% for two straight quarters, and downgrade to bearish if forward EPS estimates fall below $7.00 or the $82.50 November low breaks.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Henry Schein's 12-month outlook, with a consensus price target around $96.60 and implied upside of +13.7% versus the current price.
Average Target
$96.60
16 analysts
Implied Upside
+13.7%
vs. current price
Analyst Count
16
covering this stock
Price Range
$64 - $110
Analyst target range
Coverage is solid with 15 analysts, and the tone is constructive: 8 Buy ratings, 7 Hold, and 1 Sell, yielding a consensus recommendation of "buy" (mean score 2.375 on a scale where lower is more bullish). The average target price of $96.60 implies roughly 12.0% upside from the current $86.22, a moderate but meaningful expected return that aligns with the stock's steady-uptrend technical profile. The distribution leans bullish but is not euphoric — the 7 Hold ratings indicate a substantial contingent waiting for proof that margin recovery and EPS growth can be sustained.\n\nThe target range is wide, from a low of $64.00 to a high of $110.00 — a spread of 72% of the current price — which signals genuine disagreement about the trajectory. The $110 high target likely assumes continued gross-margin expansion toward 30%+, successful buyback-driven EPS accretion, and multiple expansion toward the mid-teens forward PE; the $64 low target implies margin compression, competitive pressure in dental distribution, and a de-rating toward the stock's historical trough multiples. Institutional ratings show a stable-to-positive pattern: Evercore ISI reiterated Outperform on November 4, Barclays and Citigroup maintain Overweight/Buy, and UBS and Leerink remain Neutral/Market Perform — no recent downgrades, but also no fresh upgrades, suggesting analysts are in a wait-and-see posture heading into year-end. The consensus forward EPS estimate of $7.25 against a $96.60 average target implies a target multiple of roughly 13.3x forward earnings, a reasonable anchor for a low-growth distributor.
Bulls vs Bears: HSIC Investment Factors
The bull case rests on a concrete, quantifiable setup: 14.35x forward earnings against a 23.1x trailing multiple, a 7% share-count reduction from buybacks, gross margin up 110 basis points year over year, and a 12% implied return to the $96.60 average target. The bear case is equally grounded: 3.95% revenue growth with no acceleration, a trailing PE near the top of its 19.3x–25.8x historical band, 5.1x interest coverage, and a Q1 cash-flow outflow that shows how fragile a low-margin distributor's working capital can be. On balance the bull evidence is modestly stronger — the forward multiple, buyback accretion, and margin trajectory are hard numbers, whereas the bear case leans on the risk that expected EPS growth fails to arrive. The single most important tension is whether the $7.25 forward EPS estimate is actually delivered: at 14.35x the stock is cheap if it is, but the 23.1x trailing multiple means the market has already paid for that step-up, so a miss would compress the multiple from both directions at once.
Bullish
- Forward PE of 14.35x looks undemanding: The stock trades at 23.1x trailing earnings but only 14.35x the $7.25 consensus forward EPS, a 38% compression that implies the market expects a meaningful earnings step-up. For a distributor with 3.95% revenue growth and a 5.7% FCF yield, that forward multiple is below where such cash-generative franchises typically settle.
- Gross margin recovery is real: Q3 gross margin expanded to 29.79% from 28.69% a year ago, and the trailing gross margin of 29.14% reflects a genuine recovery from the depressed levels of prior years. Net income rose to $119 million (3.43% margin) from $101 million (3.02%), showing operating leverage is beginning to flow through.
- Buybacks are shrinking the share count fast: Diluted shares fell from 121.0 million in Q3 2025 to 112.5 million in Q3 2026, a roughly 7% reduction, with over $500 million repurchased across the trailing four quarters and $125 million in Q3 alone. At 14.35x forward earnings, this is highly accretive to per-share results even with flat absolute earnings.
- Analyst consensus and target imply 12% upside: Fifteen analysts split 8 Buy / 7 Hold / 1 Sell, yielding a consensus 'buy' (mean 2.375) and an average target of $96.60 versus the $86.22 price — roughly 12.0% implied upside. The $110 high target implies a mid-teens forward multiple, achievable if margin expansion continues.
Bearish
- Trailing PE near top of historical band: At 23.1x trailing earnings, HSIC sits near the upper end of its two-year range of roughly 19.3x to 25.8x, with the 2023 trough near 17.7x. If the expected forward EPS step-up disappoints, the trailing multiple offers little cushion and a de-rating toward the high-teens would imply meaningful downside.
- Growth is slow and not accelerating: Q3 revenue of $3.471 billion grew just 3.95% year over year, and the quarterly cadence ($3.368B, $3.458B, $3.471B) shows no inflection. With Healthcare Distribution at $2.953 billion of the $3.471 billion total, consolidated growth is hostage to dental-market utilization and pricing rather than any step-change catalyst.
- Leverage consumes a large share of operating profit: Interest expense of $42 million against $215 million of operating income gives coverage of only about 5.1x, and the gap between operating income ($215M) and pre-tax income ($163M) shows leverage eats roughly a quarter of operating profit. Debt-to-equity of 1.14x with just $184 million of cash against a $9.2 billion market cap leaves little liquidity cushion.
- Lumpy and weak cash conversion: Despite $529 million of trailing free cash flow, Q1 free cash flow was -$136 million on a $278 million working-capital outflow, followed by only $196 million in Q2 and $131 million in Q3. A soft Q3 cash-flow print in a low-margin distribution model raises questions about the durability of the FCF yield that underpins the valuation.
HSIC Technical Analysis
Henry Schein is in a sustained, if unspectacular, uptrend: the stock is up 17.56% over the past year and 12.24% year to date, and at $86.22 it sits at roughly 74.5% of its 52-week range of $68.70 to $92.18. That positioning — comfortably in the upper half of the range but still about 6.5% below the high — suggests constructive momentum without the overextension that typically accompanies a blow-off top, leaving room for further upside before the stock tests its ceiling. The 17.56% one-year gain also outpaces the S&P 500's 12.27% advance, a relative-strength spread of 5.29 points that confirms genuine outperformance rather than beta-driven drift.\n\nShort-term momentum is more mixed and reveals a deceleration pattern. The stock is up just 0.77% over the past month and down 3.95% over three months, a sharp contrast to the 18.56% six-month gain — meaning essentially all of the year's advance was booked in the spring and early summer, with the last quarter spent consolidating. Notably, the one-month relative strength versus SPY is a healthy +3.03 points even as the three-month relative strength is -1.12 points, implying the stock has recently stabilized and begun to outperform a weakening tape (SPY -2.26% over one month) after a mid-cycle pullback. The 180-day price series shows a clear stair-step: a rally from ~$72.69 in mid-May to ~$90.74 by mid-August, followed by a choppy $82.50–$88.74 range through November, with the November 3 dip to $82.50 immediately reversed by a $88.24 close the next session — a bullish rejection of lower prices.\n\nKey technical levels are well defined. Support sits at the 52-week low of $68.70, with a nearer intermediate floor around the $82.50 November swing low; resistance is the $92.18 52-week high, and a decisive breakout above that level would signal the consolidation has resolved to the upside and likely open a new leg higher. A breakdown below $82.50 would instead flag a failed rally and refocus attention on the $68.70 low, a roughly 20% downside scenario. With a beta of 0.856, Henry Schein is about 14% less volatile than the market, which argues for larger position sizing per unit of risk and makes the stock a relative defensive within healthcare distribution; the max drawdown of -17.23% over the period is consistent with that muted volatility profile.
Beta
0.86
0.86x market volatility
Max Drawdown
-17.2%
Largest decline past year
52-Week Range
$69-$92
Price range past year
Annual Return
+18.9%
Cumulative gain past year
| Period | HSIC Return | S&P 500 |
|---|---|---|
| 1m | -1.6% | -3.0% |
| 3m | -4.8% | -3.6% |
| 6m | +16.0% | -0.2% |
| 1y | +18.9% | +10.1% |
| ytd | +10.6% | +8.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HSIC Fundamental Analysis
Revenue growth is steady but slow. Third-quarter fiscal 2026 revenue of $3.471 billion rose 3.95% year over year from $3.339 billion, extending a consistent low-single-digit cadence: $3.368 billion in Q1, $3.458 billion in Q2, and $3.437 billion in the prior-year Q4. The segment mix shows Healthcare Distribution at $2.953 billion dwarfing Technology at $221 million, so the consolidated growth rate is essentially a function of the core distribution franchise, which is growing in line with dental-market utilization and pricing rather than any step-change catalyst. The trajectory is stable but not accelerating, which caps the multiple the market is willing to pay and puts the onus on margin and buyback execution to drive EPS.\n\nProfitability is improving from a low base. Q3 net income was $119 million on a 3.43% net margin, up from $101 million and a 3.02% margin in the year-ago quarter, while gross margin expanded to 29.79% from 28.69% and operating margin rose to 6.19% from 6.17%. The sequential gross-margin path — 31.77% in Q1, 31.84% in Q2, 29.79% in Q3 — shows some quarterly noise, but the trailing gross margin of 29.14% and operating margin of 5.75% remain thin in absolute terms, typical of a low-margin distributor where scale and working-capital efficiency matter more than pricing power. Interest expense of $42 million against $215 million of operating income (interest coverage of roughly 5.1x) is a meaningful drag, and the gap between operating income and pre-tax income ($163 million) highlights how leverage consumes a sizable share of operating profit.\n\nThe balance sheet is adequate but not fortress-like. Debt-to-equity stands at 1.14x with a current ratio of 1.38x, and cash of just $184 million against a $9.2 billion market cap means the company relies on revolving credit and cash flow rather than a large liquidity cushion. Free cash flow is the bright spot — $529 million trailing twelve months, a 5.7% FCF yield on the $9.2 billion market cap — though the quarterly pattern is lumpy, with Q1 free cash flow of -$136 million (driven by a $278 million working-capital outflow) followed by $196 million in Q2 and $131 million in Q3. ROE of 12.27% and ROA of 4.39% are respectable for a distributor but reflect the leveraged capital structure; the company funds growth internally and returns capital via buybacks ($125 million in Q3 alone) rather than dividends, with a 0% payout ratio.
Quarterly Revenue
$3.5B
2026-09
Revenue YoY Growth
+4.0%
YoY Comparison
Gross Margin
29.8%
Latest Quarter
Free Cash Flow
$529000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HSIC Overvalued?
Because Henry Schein is solidly profitable (Q3 net income of $119 million, trailing EPS positive), the PE ratio is the appropriate primary metric. The stock trades at 23.1x trailing earnings but only 14.35x forward earnings — a 38% compression that implies the market expects meaningful EPS growth, consistent with the $7.25 consensus forward EPS estimate versus the current run-rate. That forward multiple is the more relevant anchor for a distributor with low-single-digit revenue growth, and at 14.35x it looks undemanding in absolute terms.\n\nRelative to its own sector, the picture is mixed. The 0.70x price-to-sales ratio is low for healthcare, but that is structurally typical of distribution businesses with 29% gross margins; the 12.65x EV/EBITDA and 1.08x EV/Sales are the more comparable metrics, and both sit in a reasonable range for a medical distributor. The 2.83x price-to-book and 3.23x PEG ratio suggest the market is paying up relative to growth, while the 12.92x price-to-cash-flow is moderate. On balance, the stock screens as fairly valued to slightly cheap on forward earnings but not statistically cheap on asset or growth-adjusted bases.\n\nHistorical context is the most cautionary input. The current 23.1x trailing PE sits near the top of the stock's recent band — historical quarterly PE ratios ranged from roughly 19.3x to 25.8x over the past two years, with the 2023 trough near 17.7x — while the price-to-sales ratio of 0.70x is actually well below the 2.4x–3.5x range seen in 2022–2024, reflecting the post-split share count and revenue base. The forward PE of 14.35x versus the trailing 23.1x is the key tell: the market is pricing in an earnings step-up, and if that materializes the stock is inexpensive, but if growth disappoints the trailing multiple offers little cushion. The 2.83x P/B is mid-range versus its own history, neither a screaming value nor a momentum extreme.
PE
23.1x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 15x~26x
vs. Industry Avg
26.2x
Industry PE ~26.2x*
EV/EBITDA
12.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on thin margins and leveraged capital structure. Gross margin of 29.14% trailing and operating margin of 5.75% leave almost no buffer, and the sequential gross-margin path (31.77% in Q1, 31.84% in Q2, 29.79% in Q3) shows 200 basis points of quarterly noise that can swing EPS materially. Interest expense of $42 million against $215 million of operating income (5.1x coverage) consumes roughly a quarter of operating profit, and with debt-to-equity at 1.14x and only $184 million of cash, the company depends on revolver access and operating cash flow. Cash conversion is lumpy — Q1 free cash flow of -$136 million on a $278 million working-capital outflow — meaning a single weak quarter can undermine the $529 million TTM FCF figure that supports the 5.7% FCF yield.
Market and competitive risks stem from valuation and the structural position of a distributor. At 23.1x trailing earnings, HSIC trades near the top of its two-year 19.3x–25.8x band, so multiple compression rather than earnings deterioration alone could drive the stock lower; the 3.23x PEG ratio shows the market is already paying up relative to growth. As a middleman in fragmented dental and physician-practice distribution, Henry Schein faces pricing pressure from manufacturers going direct and from competitors in a scale-driven, relationship-intensive channel where its 29% gross margin is structurally capped. Beta of 0.856 provides some macro insulation, but a defensive healthcare distributor is also exposed to sector rotation out of defensives during risk-on periods, and the 7 Hold ratings with no recent upgrades suggest analysts are waiting rather than adding.
The worst-case scenario is a margin-recovery stall combined with a forward EPS miss. If gross margin reverts toward the 28.7% year-ago level and the $7.25 forward EPS estimate is cut, the stock would likely de-rate toward its historical trough multiple near 17.7x trailing, which on current earnings implies a price in the low-to-mid $70s. A fuller breakdown toward the $64 analyst low target would represent roughly -26% from the current $86.22, and a retest of the $68.70 52-week low would be about -20%. The observed max drawdown of -17.23% over the past 180 days is a realistic guide to a normal correction, but a fundamental miss could exceed it given the stock sits only 6.5% below its $92.18 high with the consolidation unresolved.
FAQ
Ranked by severity: first, earnings/valuation risk — the 23.1x trailing PE near the top of its historical band means a forward EPS miss below the $7.25 consensus would compress both the trailing and forward multiples simultaneously, and the 3.23x PEG ratio leaves little growth-adjusted cushion. Second, margin risk — Q3 gross margin slipped to 29.79% from 31.84% in Q2, and a reversion toward the 28.69% year-ago level would erase the 110 basis-point year-over-year gain that underpins the recovery thesis. Third, financial/leverage risk — interest expense of $42 million against $215 million of operating income (about 5.1x coverage) consumes roughly a quarter of operating profit, and debt-to-equity of 1.14x with only $184 million of cash leaves a thin liquidity cushion. Fourth, cash-conversion and competitive risk — Q1 free cash flow was -$136 million on a $278 million working-capital outflow, and as a middleman in fragmented dental distribution HSIC faces pricing pressure from manufacturers going direct, all against a 72% analyst target spread ($64–$110) that signals genuine disagreement.
The three-scenario framework assigns a 55% probability to the base case of $90–$97, a 25% probability to the bull case of $100–$110, and a 20% probability to the bear case of $64–$75. The base case — most likely — assumes ~4% revenue growth, gross margin stabilizing at 29%–30%, and the $7.25 forward EPS delivered through buyback accretion and cost discipline, driving the stock toward the $96.60 average target at roughly 13.3x forward earnings. The bull case requires gross margin holding above 30% and analyst upgrades from the 7 Hold ratings, reaching the $110 high target near 15.2x forward EPS. The bear case assumes a margin stall and forward EPS cut below $7.00, de-rating toward the historical trough multiple and the $64 analyst low, roughly -26% from $86.22. The key assumption behind the most likely outcome is that the expected earnings step-up from 23.1x trailing to 14.35x forward actually materializes.
The answer depends on which multiple you anchor to. On trailing earnings HSIC looks full at 23.1x, near the top of its two-year 19.3x–25.8x range and well above the 2023 trough near 17.7x; on forward earnings it looks cheap at 14.35x the $7.25 consensus EPS, a 38% compression that implies the market expects a meaningful earnings step-up. Supporting metrics are mixed: the 0.70x price-to-sales is low in absolute terms but structurally normal for a 29% gross-margin distributor, while the 12.65x EV/EBITDA and 1.08x EV/sales sit in a reasonable range for medical distribution. The 2.83x price-to-book and 3.23x PEG ratio are the caution flags, showing the market is paying up relative to growth and assets. Net, the stock screens as fairly valued to slightly cheap on forward earnings but not statistically cheap on growth-adjusted or book bases — the market is pricing in the expected EPS step-up, so delivery is required to justify the price.
From a risk/reward standpoint HSIC offers a modestly positive but not compelling setup: at $86.22 it has roughly 12.0% upside to the $96.60 average analyst target against a bear-case downside of about -20% to the $68.70 52-week low, a ratio that favors patience over urgency. The valuation is undemanding on forward earnings at 14.35x the $7.25 consensus EPS, and the 5.7% free-cash-flow yield plus a 7% share-count reduction provide real per-share support. However, the 23.1x trailing PE sits near the top of its two-year 19.3x–25.8x band, and 7 of 15 analysts rate it Hold with no recent upgrades, signaling the easy money has been made after a 17.56% one-year run. The biggest downside risk is a forward EPS miss that would compress the multiple from both the trailing and forward sides at once. It is a reasonable buy for defensive, low-beta (0.856) investors seeking healthcare-distribution exposure with a 12-month horizon, but better entry points likely exist near the low-$80s (roughly 12x forward EPS) or on confirmed gross margin above 30%.
HSIC is better suited to a medium-to-long-term hold than short-term trading. Its 0.856 beta makes it about 14% less volatile than the market, and the 180-day max drawdown of -17.23% is muted, which limits the payoff from tactical trading but supports larger position sizing for patient investors. The stock is in a mature, low-growth stage (3.95% revenue growth) with no dividend (0% payout ratio), so total return depends on EPS accretion from buybacks and modest multiple re-rating rather than income or rapid expansion. Earnings visibility is reasonable but not exceptional — the 72% analyst target spread and 7 Hold ratings reflect genuine uncertainty about the margin trajectory. A suggested minimum holding period is 12–18 months, long enough to capture the Q4 print and two to three quarters of margin evidence; short-term traders should instead watch the defined technical levels of $92.18 resistance and $82.50 support for entry and exit signals.

